浙江我武生物科技股份有限公司

Changchun High-Tech Secures €177.7 Million Deal for ALK's House Dust Mite Allergy Immunotherapies in China

- Jin Sai Pharmaceuticals, a subsidiary of Changchun High-Tech, acquired exclusive rights to three house dust mite allergen-specific immunotherapy products from Danish company ALK-Abello for up to €177.7 million through 2039. - The deal includes two immunotherapy products and one diagnostic kit, with ACARIZAX being the world's first sublingual immunotherapy tablet approved for allergic asthma and allergic rhinitis in multiple countries. - This strategic acquisition aims to diversify Changchun High-Tech's revenue beyond its dominant growth hormone business, which has faced pricing pressure from centralized procurement programs. - China represents the world's largest market for dust mite allergy patients, yet has significantly low market penetration rates for related treatments, presenting substantial commercial opportunity.